ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesE71.528

E71.528

Billable

Other X-linked adrenoleukodystrophy

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 E71.528 is a billable code used to indicate a diagnosis of other x-linked adrenoleukodystrophy.

Key Diagnostic Point:

X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder characterized by the accumulation of very long-chain fatty acids (VLCFAs) due to a deficiency in the enzyme acyl-CoA synthetase. This condition primarily affects the adrenal glands and the nervous system, leading to a variety of symptoms including adrenal insufficiency, progressive neurological decline, and behavioral changes. The disorder is caused by mutations in the ABCD1 gene located on the X chromosome, which is responsible for the transport of VLCFAs into peroxisomes for degradation. The clinical presentation can vary widely, with some individuals experiencing a childhood form that leads to rapid neurological deterioration, while others may have a milder adult-onset form. Diagnosis is typically confirmed through biochemical testing to measure VLCFA levels and genetic testing to identify mutations in the ABCD1 gene. Management of X-ALD may include hormone replacement therapy for adrenal insufficiency and supportive care for neurological symptoms. Early diagnosis and intervention are crucial for improving outcomes in affected individuals.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Genetic testing requirements for accurate diagnosis
  • Variability in clinical presentation and symptomatology
  • Need for biochemical testing to confirm VLCFA levels
  • Potential for misdiagnosis with other metabolic disorders

Audit Risk Factors

  • Inadequate documentation of genetic testing results
  • Failure to document the clinical presentation and progression
  • Misclassification of the condition due to overlapping symptoms with other disorders
  • Lack of clear linkage between diagnosis and treatment provided

Specialty Focus

Medical Specialties

Genetics

Documentation Requirements

Detailed family history, genetic test results, and clinical findings.

Common Clinical Scenarios

Patients presenting with neurological symptoms and a family history of X-linked disorders.

Billing Considerations

Ensure accurate documentation of genetic counseling and testing outcomes.

Neurology

Documentation Requirements

Neurological assessment findings, imaging results, and treatment plans.

Common Clinical Scenarios

Patients with progressive neurological decline and behavioral changes.

Billing Considerations

Document the timeline of symptom onset and progression for accurate coding.

Coding Guidelines

Inclusion Criteria

Use E71.528 When
  • Follow ICD
  • CM guidelines for coding genetic disorders, ensuring accurate documentation of the condition's clinical manifestations
  • Include any relevant laboratory results and genetic testing outcomes

Exclusion Criteria

Do NOT use E71.528 When
  • Exclude codes for other specific types of adrenoleukodystrophy that may have distinct coding

Related ICD-10 Codes

Related CPT Codes

81292CPT Code

Genetic testing for ABCD1 gene mutations

Clinical Scenario

Used when confirming a diagnosis of X-ALD.

Documentation Requirements

Document the reason for testing and results.

Specialty Considerations

Genetics specialists should ensure comprehensive family history is included.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of genetic disorders, including X-ALD. This specificity aids in better tracking of the condition and improves the accuracy of treatment and management data.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of genetic disorders, including X-ALD. This specificity aids in better tracking of the condition and improves the accuracy of treatment and management data.

Reimbursement & Billing Impact

The transition to ICD-10 has allowed for more specific coding of genetic disorders, including X-ALD. This specificity aids in better tracking of the condition and improves the accuracy of treatment and management data.

Resources

Clinical References

  • •
    National Organization for Rare Disorders (NORD)

Coding & Billing References

  • •
    National Organization for Rare Disorders (NORD)

Frequently Asked Questions

What is the primary cause of X-linked adrenoleukodystrophy?

X-linked adrenoleukodystrophy is primarily caused by mutations in the ABCD1 gene, which leads to the accumulation of very long-chain fatty acids due to a deficiency in the enzyme responsible for their breakdown.